valine and erlotinib hydrochloride

valine has been researched along with erlotinib hydrochloride in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fu, X; Ho, WT; Ishii, T; Li, Q; Li, Z; Xing, S; Xu, M; Zhao, ZJ	1
Al-Kali, A; Cherry, M; Ghabache, B; Khawandanah, M; Ozer, H; Selby, G; Srour, S; Zhao, ZJ	1
Ding, X; Dong, Y; Gu, W; Song, X; Wang, Z; Wu, Y; Zhang, W; Zheng, Y; Zhong, Y	1

Trials

1 trial(s) available for valine and erlotinib hydrochloride

Article	Year
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Annals of hematology, 2015, Volume: 94, Issue:4 Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Male; Middle Aged; Phenylalanine; Polycythemia Vera; Quinazolines; Treatment Outcome; Valine	2015

Other Studies

2 other study(ies) available for valine and erlotinib hydrochloride

Article	Year
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. The Journal of biological chemistry, 2007, Feb-09, Volume: 282, Issue:6 Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Enzyme Activation; Erlotinib Hydrochloride; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Jurkat Cells; Mice; Phenylalanine; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Valine	2007
Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma. Cell proliferation, 2018, Volume: 51, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Valine; Xenograft Model Antitumor Assays	2018

Article

Year

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.

The Journal of biological chemistry, 2007, Feb-09, Volume: 282, Issue:6

Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Enzyme Activation; Erlotinib Hydrochloride; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Jurkat Cells; Mice; Phenylalanine; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Valine

2007

Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.

Cell proliferation, 2018, Volume: 51, Issue:3

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Valine; Xenograft Model Antitumor Assays

2018